University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria.
University Clinic of Radiology, Medical University of Innsbruck, Innsbruck, Austria.
Trials. 2022 Sep 2;23(1):726. doi: 10.1186/s13063-022-06638-6.
The standard procedure for the planning of transcatheter aortic valve replacement (TAVR) is the combination of echocardiography, coronary angiography, and cardiovascular computed tomography (TAVR-CT) for the exact determination of the aortic valve dimensions, valve size, and implantation route. However, up to 80% of the patients undergoing TAVR suffer from chronic renal insufficiency. Alternatives to reduce the need for iodinated contrast agents are desirable. Cardiac magnetic resonance (CMR) imaging recently has emerged as such an alternative. Therefore, we aim to investigate, for the first time, the non-inferiority of TAVR-CMR to TAVR-CT regarding efficacy and safety end-points.
This is a prospective, randomized, open-label trial. It is planned to include 250 patients with symptomatic severe aortic stenosis scheduled for TAVR based on a local heart-team decision. Patients will be randomized in a 1:1 fashion to receive a predefined TAVR-CMR protocol or to receive a standard TAVR-CT protocol within 2 weeks after inclusion. Follow-up will be performed at hospital discharge after TAVR and after 1 and 2 years. The primary efficacy outcome is device implantation success at discharge. The secondary endpoints are a combined safety endpoint and a combined clinical efficacy endpoint at baseline and at 1 and 2 years, as well as a comparison of imaging procedure related variables. Endpoint definitions are based on the updated 2012 VARC-2 consensus document.
TAVR-CMR might be an alternative to TAVR-CT for planning a TAVR procedure. If proven to be effective and safe, a broader application of TAVR-CMR might reduce the incidence of acute kidney injury after TAVR and thus improve outcomes.
The trial is registered at ClinicalTrials.gov (NCT03831087). The results will be disseminated at scientific meetings and publication in peer-reviewed journals.
经导管主动脉瓣置换术(TAVR)的规划标准程序是结合超声心动图、冠状动脉造影和心血管计算机断层扫描(TAVR-CT),以准确确定主动脉瓣尺寸、瓣口大小和植入路径。然而,高达 80%接受 TAVR 的患者患有慢性肾功能不全。需要减少碘造影剂使用的替代方案是可取的。心脏磁共振(CMR)成像最近已成为此类替代方案。因此,我们旨在首次研究 TAVR-CMR 在疗效和安全性终点方面与 TAVR-CT 的非劣效性。
这是一项前瞻性、随机、开放标签试验。计划根据当地心脏团队的决策,纳入 250 名因症状性严重主动脉瓣狭窄而计划接受 TAVR 的患者。患者将以 1:1 的比例随机分为接受预设 TAVR-CMR 方案或在纳入后 2 周内接受标准 TAVR-CT 方案。TAVR 后在出院时、1 年和 2 年进行随访。主要疗效终点是出院时器械植入成功。次要终点是基线时和 1 年和 2 年后的联合安全性终点和联合临床疗效终点,以及比较成像程序相关变量。终点定义基于 2012 年更新的 VARC-2 共识文件。
TAVR-CMR 可能是 TAVR-CT 规划 TAVR 程序的替代方案。如果被证明是有效和安全的,TAVR-CMR 的更广泛应用可能会降低 TAVR 后急性肾损伤的发生率,从而改善结果。
该试验在 ClinicalTrials.gov 注册(NCT03831087)。结果将在科学会议上公布,并在同行评议期刊上发表。